Burden of Gastrointestinal, Liver, and Pancreatic Diseases in the United States.
By A. Peery, Seth D. Crockett, A. Barritt, E. Dellon, S. Eluri, L. Gangarosa, E. Jensen, J. Lund, S. Pasricha, T. Runge and 3 more. Gastroenterology, 2015
926 citations recorded by the source corpus.
BACKGROUND & AIMS Gastrointestinal (GI), liver, and pancreatic diseases are a source of substantial morbidity, mortality, and cost in the United States. Quantification and statistical analyses of the burden of these diseases are important for researchers, clinicians, policy makers, and public health professionals. We gathered data from national databases to estimate the burden and cost of GI and liver disease in the United States. METHODS We collected statistics on health care utilization in the ambulatory and inpatient setting along with data on cancers and mortality from 2007 through 2012. We included trends in utilization and charges. The most recent data were obtained from the Centers for Disease Control and Prevention, the Agency for Healthcare Research and Quality, and the National Cancer Institute. RESULTS There were 7 million diagnoses of gastroesophageal reflux and almost 4 million diagnoses of hemorrhoids in the ambulatory setting in a year. Functional and motility disorders resulted in nearly 1 million emergency department visits in 2012; most of these visits were for constipation. GI hemorrhage was the most common diagnosis leading to hospitalization, with >500,000 discharges in 2012, at a cost of nearly $5 billion dollars. Hospitalizations and associated charges for inflammatory bowel disease, Clostridium difficile infection, and chronic liver disease have increased during the last 20 years. In 2011, there were >1 million people in the United States living with colorectal cancer. The leading GI cause of death was colorectal cancer, followed by pancreatic and hepatobiliary neoplasms. CONCLUSIONS GI, liver and pancreatic diseases are a source of substantial burden and cost in the United States.
Subfields: Genetics, Infectious Diseases, Oncology
View Paper: https://www.semanticscholar.org/paper/691dc20b579b81708e3f1f2c807e6818628bf355
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- S. Wani
- T. Gardner
- Y. Falck-Ytter
- A. Barkun
- Seth D. Crockett
Citations in the corpus
- American Gastroenterological Association Institute Guideline on Initial Management of Acute Pancreatitis. (2018, background): “6 billion per year.(2) The incidence of AP ranges from 5 to 30 cases per 100,000, and there is evidence that the incidence has been rising in recent years.”
- Diagnosis and Treatment of Alcohol‐Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases (2020, neutral): “5 per 100,000 in 2012; the relative contribution of ALD to all cirrhosis mortality is predicted to increase as the proportion of deaths due to hepatitis C virus (HCV) cirrhosis declines.(3,6) More recently, AC mortality was shown to have increased from 2008 to 2016, particularly among patients ages ”